43 results about "Memory Dysfunction" patented technology

The present invention relates to novel compounds of formula (I) useful as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions for the prevention or therapeutic improvement of memory dysfunction, sleep and wakefulness disorders, anxiety, depression, mood disorders, seizures, obesity, diabetes, appetite and food intake Abnormalities, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorder (including bulimia), anorexia, psychosis (including manic depression), schizophrenia, delirium, dementia, catatonia, cognitive impairment , attention deficit disorder, substance use disorder, movement disorders (including Parkinson's disease), epilepsy, and addiction.

The invention relates to an application of icaritin to a medicine for treating the Alzheimer disease. Icaritin is taken as a main raw herb, and a proper amount of auxiliary materials are added to prepare an oral preparation or an injection. By deep and detailed research of icaritin on aspects, such as a pharmacological action and an action mechanism, it is found that icaritin can obviously reduce Abeta aggregation and cholinergic nerve functional impairment, due to Abeta<25-35>, of a dementia rat model, and obviously improves the learning and memory dysfunction of the dementia rat model. Icaritin can reduce Abeta aggregation and improves the function of brain cholinergic nerve, produces a function of resisting Abeta<25-35> neurotoxicity, and obviously improves the learning and memory ability of the dementia rat model. According to the invention, by researching the effects of icaritin on the learning and memory ability, the cholinergic system, and an Abeta metabolic pathway of the dementia rat model, the pharmacological action mechanism of icaritin on treating the Alzheimer disease is illustrated, and pharmacological foundations on application of further developing icaritin are provided.

A crystal form I of (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide, or named (S)-oxiracetam, is provided, which is characterized by a powder x-ray diffraction pattern that exhibits data of d-values versus the relative intensities as: 7.075(M), 5.355(S), 5.092(S), 4.590(M), 4.325(M), 4.259(S), 4.041(VS), 3.808(M), 3.542(M), 3.445(M), 3.393(M), 2.972(M), 2.914(S). A method for preparing a crystal form I of (S)-oxiracetam is also provided, which includes preparing the crude product and crystallizing A use of the crystal form I of (S)-oxiracetam in the manufacture of a medicament for preventing and treating memory dysfunction is also provided. Accordingly, the crystal form I of (S)-oxiracetam prepared by the method has high purity of more than 99.3% based on the percentages of the mass, with better efficacy than (S)-oxiracetam for preventing or treating memory dysfunction. Concerning the way of charging materials, adding inorganic base only a few times is simpler and more beneficial to industrial manufacturing and application.

A computer based method and system forms measurements of brain function and predictions of a likelihood for memory impairment via the use of cameras, including a near-infrared (NIR) spectroscopic device and a camera capturing images in the Red-Green-Blue (RGB) spectrum. The device acquires from a subject measurements of ions, molecules, or combinations thereof at more than one moment in time, as well as amplitude and timing of blood pulsations. Based on the measured molecule or ion concentration, flow, and so forth, a processor assesses the probability of a neuron to form an action potential. Formation of an action potential increases the probability that the subject individual will create a memory.

The invention discloses a traditional Chinese medicine composition, a preparation method and application thereof. The traditional Chinese medicine composition is composed of Coptidis Rhizoma Cortex Phellodendron, Cortex Phellodendri, Gardenia, Salvia Miltiorrhiza, Curcuma longa and Shichangpu. The traditional Chinese medicine composition can significantly improve the learning and memory dysfunction of 5×FAD transgenic mice, reduce the expression of Aβ40 / 42 in the hippocampus, and increase the 5 The expression levels of pre- and post-synaptic proteins in the hippocampus of ×FAD transgenic mice can improve the excitatory synaptic transmission disorder in the hippocampus of 5×FAD mice, and at the same time inhibit the apoptosis of hippocampal neurons and the proliferation of microglia in 5×FAD mice In addition, it can inhibit the expression of inflammatory factors in the serum and hippocampus of 5×FAD mice, which provides a reliable theoretical basis for the preparation of drugs for the treatment or adjuvant treatment of Alzheimer's disease.

The invention discloses the application of lithium tungstate in pharmaceuticals, especially in the preparation of drugs for treating neurodegenerative diseases, neuropathy caused by diabetes, and cerebral ischemia including brain dysfunction. Since lithium tungstate anion and cation are both active, the two play a synergistic effect and can better inhibit the activity of GSK-3. By inhibiting the activity of GSK-3α, reducing the production of Aβ to reduce SP; by inhibiting the activity of GSK-3β, inhibiting the hyperphosphorylation of tau protein to reduce NFT. By increasing the content of BDNF in cortical neurons, it can promote the survival and repair of nerve cells in the state of ischemia and hypoxia, and improve learning and memory dysfunction.

A method for relieving memory dysfunction using Puerariae Radix Extract is provided, including decocting Puerariae Radix in water, concentrating the extracted product thereof, and administrating an effective dose of the Puerariae Radix extract to a subject. Since the present invention merely uses Puerariae Radix as an ingredient, it belongs to a Chinese herbal medicine of single drug prescription. Further, with the same amount of Puerarin, Puerariae Radix Extract of the present invention provides a better neuroprotective effect in comparison with Puerarin, which indicates that the Puerariae Radix extract contains more active neurotrophic ingredients other than Puerarin. Therefore, Puerariae Radix extract is more promising potential therapeutic medicine than Puerarin for relieving the symptoms of anxiety and cognitive impairment.

The invention provides a crystal form of dextrorotation oxiracetam, the crystal form has a diffraction angle of 2 θ is There are diffraction peaks at 17.12±0.2°, 18.88±0.2°, 19.24±0.2°, 21.18±0.2°, and 24.88±0.2°. This crystal form has oxiracetam that can promote the synthesis of phosphorylcholine and o-acylethanolamine, and promote the brain Metabolism, has a stimulating effect on specific central nervous pathways through the blood-brain barrier, improves intelligence and memory, has obvious advantages on memory dysfunction, and has special biological activities in the fields of sedation and anti-epilepticus. The preparation method of the crystal form of the invention is simple and suitable for industrial production.